

QNZ

Catalog No: tcsc1515



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

545380-34-5

Formula:

$C_{22}H_{20}N_4O$

Pathway:

Apoptosis;NF-κB

Target:

TNF Receptor;NF-κB

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 37 mg/mL (103.81 mM)

Alternative Names:

EVP4593

Observed Molecular Weight:

356.42


Product Description

QNZ shows strong inhibitory effects on **NF-κB** transcriptional activation and **TNF-α** production with **IC₅₀**s of 11 and 7 nM, respectively. EVP4593 is a neuroprotective inhibitor of **SOC** channel.

IC50 & Target: IC50: 7 nM (TNF-α), 11 nM (NF-κB)^[1]

SOC Channel^[2]

In Vitro: QNZ (Compound 11q) has a suppressing effect of the NF-κB mediated-inflammatory response. QNZ inhibits edema formation dose-dependently^[1]. QNZ (EVP4593) reduces the number of lysosomes/autophagosomes and store-operated channel (SOC) currents in Huntington's disease (HD). Normalization of calcium transport within neurons in response to QNZ is expected to reduce pathology manifestation. A number of lysosomes/autophagosomes are evaluated in HD and WT neurons treated with QNZ using transmission electron microscopy (TEM). Incubation with QNZ reduces the number of lysosomes/autophagosomes in HD GABAergic medium spiny (GABA MS)-like neurons (GMSLNs) by almost two-fold (from 0.41 ± 0.04 to 0.23 ± 0.04 ; p[2]).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!